COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

CPTAC Study Identifies Unique Linkage of Glycosylation to Ovarian Cancer

Protein glycosylation, the enzymatic process that attaches glycans or sugar molecules to proteins, plays a crucial role in cancer development processes, such as cell-cell adhesion, cell growth, ligand-receptor binding, and tumor metastasis. Aside from phosphorylation, other protein modifications have not been investigated in large-scale proteomic studies.


Improved BASIL Workflow Provides Precise and Robust Protein Profiling for Single-Cell Analysis

Almost 18 months ago, CPTAC researchers from theIntegrative Omics Group at Pacific Northwest National Laboratory (PNNL), developed a stream-lined technique to increase the sensitivity of peptide phospho-group identification during mass spectral analysis.  The solution, called the ‘


In Case You Missed It: CPTAC Junior Investigator Spotlight (Part 1)

In case you missed it, this third article (part 1 of 2) in the Investigator Spotlight Series, developed and written by Dr.


New Proteogenomic Data Release for CPTAC Lung Squamous Cell Carcinoma Discovery Study!

Announcing our newest data release for the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Lung Squamous Cell Carcinoma (LSCC) Discovery study!  Because LSCC accounts for about 30% of all lung cancers and has a ~20% 5-year survival rate, it’s imperative that cancer


AutoRT - Using Peptide Retention Time Prediction to Accurately Determine Quality of Peptide Identification

In a recent issue of Nature Communications, Clinical Proteomics Tumor Analysis Consortium (CPTAC) researchers from Bing Zhang’s lab at Baylor College of Medicine describe a new bioinformatics software tool developed to evaluate the quality of variant peptide identifications.  Using a deep learning algorithm, the software


The CPTAC Virtual Symposium - Sept 22, 2020

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce its Virtual Scientific Symposium 2020, September 22nd, 2020.    This year’s symposium will feature talks by leaders in the field of proteogenomics and will focus on CPTAC’s tumor characterization and translational studies for pediatric brain cancer, acute myeloid leukemia,


SBIR Proteomics Technologies Funding Announcement: Single-Cell Unbiased Discovery

The NCI’s Small Business Innovation Research (SBIR) Development Center has released a program solicitation (PHS 2021-1) which includes a new, Clinical Proteomic Tumor Analysis Consortium (CPTAC)-inspired grant.  The announcement calls for the development of hig


In Case You Missed It: CPTAC Investigator Spotlight on David Fenyö and Emily Kawaler

This article is the second in the Investigator Spotlight Series that was the brain child of Dr. Dawn Hayward, a NCI Communications Fellow at OCCPR, highlighting our CPTAC researchers and thier work.  In case you missed it the first time, here she features CPTAC scientists Dr. David Fenyö and researcher Emily Kawaler!


Fred Hutch Team Establishes a New CLIA Lab for Running Targeted-MS assays, Including a Novel CLIA-Approved HER2 Test

A major goal for NCI’s Cancer Proteomic Tumor Analysis Consortium (CPTAC) is to translate proteomic technologies into clinical use to improve treatment and diagnosis of cancer.  Dr. Amanda Paulovich and team from the Fred Hutchinson Cancer Research Center (members of the CPTAC Consortium) have achieved an important milestone in this regard, by establishing a Clinical Laboratory Improvement Amendments (CLIA) - certified laboratory for running targeted proteomic assays based on multiple reaction monitoring (MRM) mass spectrometry (MS).


Pages